蹤獲觴豐

Byung-Chul (Ben) Suh is an experienced pharmaceutical scientist with a focus on CNS neuroscience and medicinal chemistry. Currently serving as Associate Director at Alkermes since June 2021, Byung-Chul has previously held significant roles, including Principal Scientist at Enanta Pharmaceuticals, where responsibilities included managing external chemistry projects targeting antiviral diseases. At Genosco, Byung-Chul led multiple kinase projects and contributed to the design of GNS-1480, a notable EGFR selective inhibitor licensed to Yuhan Corporation and subsequently to Janssen Biotech. Early career experience includes research at the Broad Institute and a postdoctoral fellowship at Harvard University, following a solid educational foundation with a PhD in Chemistry from The Johns Hopkins University and degrees in Pharmacy from Seoul National University.